英国糖尿病医师协会与英国肾脏协会联合临床实践指南:成人2型糖尿病合并慢性肾脏病高血糖的药物管理
该指南由英国糖尿病医师协会与英国肾脏协会多学科团队制定,基于最新证据更新了成人2型糖尿病合并慢性肾脏病高血糖的药物管理推荐。近期试验显示SGLT-2抑制剂、非甾体类盐皮质激素受体拮抗剂和GLP-1受体激动剂可降低肾脏复合终点事件和心血管风险。指南总结了关键推荐和临床考虑,供初级和二级医疗专业人员使用。
要点
- SGLT-2抑制剂、nsMRA和GLP-1 RA可降低T2DM合并CKD患者的肾脏复合终点和心血管风险。
- 高血糖和高血压是预防CKD发生和进展及心血管疾病的可调控危险因素。
- 指南为多学科团队制定,适用于初级和二级医疗中治疗T2DM合并CKD的医务人员。
核心结论
- 近期临床试验证明SGLT-2抑制剂、非甾体类盐皮质激素受体拮抗剂和GLP-1受体激动剂可降低T2DM合并CKD患者的肾脏复合终点事件和心血管风险。
研究设计与样本
- 该指南由英国糖尿病医师协会与英国肾脏协会的糖尿病肾脏病临床专业组制定,基于叙述性综述和证据批判性评估,2025年简版更新由多学科团队完成。
主要发现
- SGLT-2抑制剂、nsMRA和GLP-1 RA在T2DM合并CKD患者中显示降低肾脏复合终点事件(肾功能显著下降、需要肾脏替代治疗和肾脏相关死亡)和心血管风险。
- 糖尿病合并CKD患者发病率和死亡率高,主要与心血管疾病相关。
临床怎么用
- 指南为初级和二级医疗中治疗T2DM合并CKD患者的医务人员提供了关键推荐和临床考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A growing and significant number of people with diabetes develop chronic kidney disease (CKD), and diabetes-related CKD is a leading cause of end-stage kidney disease (ESKD). People with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Hyperglycemia and hypertension are modifiable risk factors to prevent the onset and progression of CKD and related CVD. Recent clinical trials of people with type 2 diabetes mellitus (T2DM) and CKD have demonstrated reduction in composite kidney end point events (significant decline in kidney function, need for kidney replacement therapy, and kidney-related death) and cardiovascular risk with sodium-glucose cotransporter 2 (SGLT-2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) and glucagon-like peptide 1 (GLP-1) receptor agonists (RAs). The Association of British Clinical Diabetologists and UK Kidney Association Diabetic Kidney Disease Clinical Speciality Group have previously undertaken a narrative review and critical appraisal of the available evidence to inform clinical practice guidelines for the pharmacological management of hyperglycemia in adults with T2DM and CKD. This 2025 abbreviated updated guidance by a multidisciplinary group of health care professionals from primary and secondary care settings summarizes the key recommendations, clinical considerations and recent evidence that has implications for clinical practice for health care professionals who treat people with T2DM and CKD.
引用
- Karalliedde J, McCafferty K, Winocour P, et al. Association of British Clinical Diabetologists and UK Kidney Association Joint Clinical Practice Guidelines for the Pharmacological Management of Hyperglycemia in Adults With Type 2 Diabetes Mellitus and CKD. Kidney Int Rep. 2025. PMID: 41141497. doi:10.1016/j.ekir.2025.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。